Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 13 - Drugs for disorders of the urinary system
Patents for A61P 13 - Drugs for disorders of the urinary system (56,135)
10/2004
10/27/2004EP1470826A1 Decoy-containing pharmaceutical compositions and method of using the same
10/27/2004EP1470257A2 RNA INTERFERENCE MEDIATED INHIBITION OF NF-KAPPA B/REL-A GENE EXPRESSION USING SHORT INTERFEREING NUCLEIC ACID (siNA)
10/27/2004EP1470256A2 RNA INTERFERENCE MEDIATED INHIBITION OF GASTRIC INHIBITORY POLYPEPTIDE /GIP) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
10/27/2004EP1470150A2 Corticosteroids nitrate derivatives
10/27/2004EP1470137A1 Edg receptor agonists
10/27/2004EP1470126A1 N-substituted spiropiperidine compounds as ligands for orl-1 receptor
10/27/2004EP1470124A1 2-(PYRIDIN-2-YLAMINO)-PYRIDO 2,3-d]PYRIMIDIN-7-ONES
10/27/2004EP1470112A1 Substituted pyridazinones as inhibitors of p38
10/27/2004EP1469884A1 Aldosterone antagonist and non-steroidal anti-inflammatory agent combination therapy to prevent or treat cardiovascular disorders
10/27/2004EP1469857A1 Use of pde5 inhibitors in the treatment of scarring and fibrosis
10/27/2004EP1469853A1 Use of 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)thieno(2,3-d-pyrimidine for treating of urinary incontinence
10/27/2004EP1469846A2 Treatment of pain, inflammation, and inflammation-related disorders with a combination of a cyclooxygenase-2 selective inhibitor and aspirin
10/27/2004EP1469834A1 Multi-stage oral drug controlled-release system
10/27/2004EP1469812A2 Oral insulin therapy
10/27/2004EP1373263B1 Heterocyclic compounds for aging-related and diabetic vascular complications
10/27/2004EP1246791B1 Aminomethyl-phenyl-cyclohexanone derivatives
10/27/2004EP0970073B1 Process for preparing eprosartan
10/27/2004EP0831791B1 Delivery of drugs to the lower gi tract
10/27/2004CN1541275A Glycoprotein and process for producing same
10/27/2004CN1541262A Hops extracts, method for prodn. and use
10/27/2004CN1541220A 17 alfa, 21-dihydroxypregnene esters as antiandrogenic agents
10/27/2004CN1541211A Derivatives of N-(arylsulfonyl) beta-aminoacids comprising substituted aminomethyl group, prepn. method thereof and pharmaceutical compsns. contg same
10/27/2004CN1541208A 2-anilino-pyrimidine derivatives as cyclin dependent kinase inhibitors
10/27/2004CN1541099A Arylazo-substituted imidazole for treatment of stress urinary incontinence
10/27/2004CN1539424A Drop pills of Finasteride and preparation technique
10/27/2004CN1172918C Isothizole derivatives useful anticancer agents
10/27/2004CN1172911C Phtalimido arylpiperazines as alpha IA receptor antagonists useful in the treatment of benign prostatic hyperplasia
10/27/2004CN1172716C Medicinal powder for treating nephritis
10/27/2004CN1172671C Medicial composition for oral administration
10/26/2004US6809214 Shortened synthesis of 3,3-diarylpropylamine derivatives
10/26/2004US6809119 Branched chain amino acid-dependent aminotransferase inhibitors and their use in the treatment of neurodegenerative diseases
10/26/2004US6809113 For therapy of arthritis, asthma, atherosclerosis, diabetic nephropathy, inflammatory bowel disease, crohn's disease, multiple sclerosis, nephritis, pancreatitis, pulmonary fibrosis, psoriasis, restenosis transplant rejection
10/26/2004US6809108 Selective muscarinic m3 receptor antagonts; reduced side effects
10/26/2004US6809098 Compounds
10/26/2004US6809092 1,3,4,5-tetrahydro-2h-2-benzazepin-2-yl derivatives; cysteine protease inhibitors
10/26/2004US6809090 Nitrogen monoxide synthase and/or lipidic peroxidation inhibitors
10/26/2004US6809089 Sulfonylaminocarboxylic acid N-arylamides as guanylate cyclase activators
10/26/2004US6809077 A cyclic polypeptides; immunosuppressive anti-inflammatory activity, inhibiting antigen-induced inflammatory cell infiltration
10/26/2004CA2080462C Therapeutic uses of actin-binding compounds
10/21/2004WO2004089936A1 Heteroarylsulfonanilide derivative and medicinal composition containing the same
10/21/2004WO2004089905A1 N-[(piperazinyl)hetaryl]arylsulfonamide compounds with affinity for the dopamine d3 receptor
10/21/2004WO2004089900A1 Azabicyclo derivatives as muscarinic receptor antagonists
10/21/2004WO2004089872A1 Highly pure bases of 3,3-diphenyl propylamine monoesters
10/21/2004WO2004089384A1 Remedy or preventive for low turnover bone diseases
10/21/2004WO2004089379A2 Pharmaceutical combination containing tamsulosin and a non-steroidal anti-inflammatory drug
10/21/2004WO2004089364A1 Azabicyclo derivatives as muscarinic receptor antagonists
10/21/2004WO2004089363A1 Substituted azabicyclo hexane derivatives as muscarinic receptor antagonists
10/21/2004WO2004009556A9 4-(substituted aryl)-5-hydroxyisoquinolinone derivative
10/21/2004WO2003062241A8 Fused heterocyclic succinimidecompounds and analogs thereof, modulators of nuclear hormone receptor function
10/21/2004WO2003045228A3 Methods for treating autoimmune disorders, and reagents related thereto
10/21/2004US20040210080 3-(oxo, oxime, hydrazone, or alkylidene)-fluorene derivatives; can be synergistically combined with other anticarcinogenic, anticholesterol, anxiolytic agents, antidepressants or enzyme inhibitors; bone disorders
10/21/2004US20040210052 Efficient synthesis of 5-heteroatom-containing-pyrazoles
10/21/2004US20040209960 particularly tetrodotoxin-resistant sodium channel modulators and/or activity-dependent sodium channel modulators, including but are not limited to compounds that modulate or interact with Nav.1.8 and/or Nav1.9 channels such as Ralfinamide, Ambroxol, and Topiramate
10/21/2004US20040209938 Novel 1,3-dihydro-2H-indol-2one derivatives, process for preparing them and pharmaceutical compositions containing them
10/21/2004US20040209934 Protein phosphate inhibitors
10/21/2004US20040209908 New derivatives of hydantoins, thiohydantoins, pyrimidinediones and thioxopyrimidinones, their preparation processes and their use as medicaments
10/21/2004US20040209901 substituted 2,4,8-trisubstituted-8H-pyrido[2,3-d]pyrimidin-7-one compounds, e.g., 8-(2,6-Difluoro-phenyl)-4-(4-fluoro-2-methyl-phenyl)-2-(2-hydroxy-1-hydroxymethyl-ethylamino)-8H-pyrido[2,3-d]pyrimidin-7-one; CSBP/p38 kinase inhibitors.
10/21/2004US20040209894 e.g., 1-(4-chloroanilino)-4-[2-(pyridin-3-yl)-ethyl]-isoquinoline and 5-[4-(tert-butyl)-anilino]-8-[(6-methoxy-pyridin-3-yl)-methyl]-[1,6]naphthyridine
10/21/2004US20040209856 Oral pharmaceutical products containing 17beta-estradiol-3-lower alkanoate, method of administering the same and process of preparation
10/21/2004US20040209832 RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
10/21/2004US20040208941 Compositions for removal of toxins
10/21/2004CA2809195A1 Stem-cell, precursor cell, or target cell-based treatment of multi-organ failure and renal dysfunction
10/21/2004CA2784829A1 Stem-cell, precursor cell, or target cell-based treatment of multi-organ failure and renal dysfunction
10/21/2004CA2522071A1 Azabicyclo derivatives as muscarinic receptor antagonists
10/21/2004CA2521989A1 Azabicyclo derivatives as muscarinic receptor antagonists
10/21/2004CA2521788A1 Substituted azabicyclo hexane derivatives as muscarinic receptor antagonists
10/21/2004CA2521632A1 Pharmaceutical combination containing tamsulosin and a non-steroidal anti-inflammatory drug
10/21/2004CA2520770A1 Agent for treating or preventing low-turnover bone diseases
10/21/2004CA2505848A1 Highly pure bases of 3,3-diphenyl propylamine monoesters
10/20/2004EP1469077A1 Cell-specific expression/replication vector
10/20/2004EP1468110A2 Molecular signatures of commonly fatal carcinomas
10/20/2004EP1468091A2 Transmembrane protein
10/20/2004EP1468020A2 Multimers of receptor-binding ligands
10/20/2004EP1468019A2 Secreted protein
10/20/2004EP1468018A2 Leptin proteins
10/20/2004EP1467998A1 Tetracyclic heterocompounds as estrogen receptor modulators
10/20/2004EP1467995A2 Pyrrolopyrimidine a2b selective antagonist compounds, their synthesis and use
10/20/2004EP1467982A1 Glucocorticoid mimetics, methods of making them, pharmaceutical formulations containing them, and uses thereof
10/20/2004EP1467979A2 FUSED HETEROCYCLIC COMPOUNDS AND ANALOGS THEREOF: MODULATORS OF NUCLEAR HORMONE RECEPTOR FUNCTION
10/20/2004EP1467976A1 N-pyrazinyl-phenylsulphonamides and their use in the treatment of chemokine mediated diseases
10/20/2004EP1467974A1 Benzimidazole derivatives and their use as gnrh antagonists
10/20/2004EP1467760A2 Systems and methods for photodynamic therapy
10/20/2004EP1467752A1 HUMAN MAST CELL−EXPRESSED MEMBRANE PROTEINS
10/20/2004EP1467733A1 2-oxo-benzimidazolyl substituted ethanolamine derivatives and their use as beta3 agonists
10/20/2004EP1467728A1 Pharmaceutical compositions comprising valsartan and nep inhibitors
10/20/2004EP1467714A1 Drug mixture with enhanced dissolution rate
10/20/2004EP1467712A1 Bilayer pharmaceutical tablet comprising telmisartan and a diuretic
10/20/2004EP1289964B1 Substituted 1-aminoalkyl-lactams and their use as muscarinic receptor antagonists
10/20/2004EP1263725B1 Novel compounds
10/20/2004EP1230236B1 Compound with growth hormone releasing properties
10/20/2004EP1206473B1 Isomeric fused pyrrolocarbazoles and isoindolones
10/20/2004EP1056720B1 Phtalimido arylpiperazines as alpha 1a receptor antagonists useful in the treatment of benign prostatic hyperplasia
10/20/2004EP1002791B1 Aminoethylphenoxyacetic acid derivatives and drugs for pain remission and calculi removal promotion in urinary lithiasis
10/20/2004EP0830136B1 New cryptophycins from synthesis
10/20/2004CN1538972A 腺苷a3受体激动剂 A3 adenosine receptor agonists
10/20/2004CN1538970A Thieno [2,3-d] pyrimidinediones and use in modulation of autoimmune disease
10/20/2004CN1538969A Novel benzothienyl or indole derivatives, preparation and use thereof as inhibitors of prenyl transferase proteins
10/20/2004CN1538966A 喹唑啉酮衍生物 Quinazolinone derivatives
10/20/2004CN1538960A Amino-phthalazinone derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions containint them
10/20/2004CN1538959A Fused-polycyclic compounds
1 ... 289 290 291 292 293 294 295 296 297 298 299 300 301 302 303 304 305 306 307 308 309 ... 562